Spectrum Pharmaceuticals, Inc. (SPPI)
| Market Cap | 498.32M |
| Revenue (ttm) | 109.33M |
| Net Income (ttm) | -160.26M |
| Shares Out | 131.46M |
| EPS (ttm) | -1.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 4 |
| Last Price | $3.20 |
| Previous Close | $3.28 |
| Change ($) | -0.09 |
| Change (%) | -2.59% |
| Day's Open | 3.30 |
| Day's Range | 3.11 - 3.31 |
| Day's Volume | 1,004,381 |
| 52-Week Range | 1.74 - 5.24 |
Spectrum Pharma is down due to two resolvable issues. If the Rolontis PDUFA issue is resolved, the stock may shoot up.
Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q3 2020 Results - Earnings Call Transcript
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...
Spectrum Pharmaceuticals (SPPI) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.
Investors need to pay close attention to Spectrum (SPPI) stock based on the movements in the options market lately.
Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q2 2020 Results - Earnings Call Transcript
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 12.12% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
The company announced the pricing of a public offering of common stock.
Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) announced good news for cancer patients in its midstage trial on Tuesday.
Spectrum scores a key win in the clinic with its experimental lung cancer drug.
These hidden gems have the potential to deliver significant returns to their shareholders over the long run.
Spectrum Pharma (SPPI) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?
Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.
Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joseph Turgeon on Q1 2020 Results - Earnings Call Transcript
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?
Shares jumped even though the company reported disappointing earnings. What can explain the boost?
Spectrum Pharma (SPPI) misses bottom-line estimates for the fourth quarter and records no revenues. Shares down.
Spectrum Pharmaceuticals, Inc.'s (SPPI) CEO Joseph Turgeon on Q4 2019 Results - Earnings Call Transcript
Progress of its pipeline candidates is likely to have increased Spectrum Pharmaceuticals' (SPPI) operating expenses in the fourth quarter.
Spectrum Pharmaceuticals (SPPI) closed the most recent trading day at $3.24, moving -1.52% from the previous trading session.
Spectrum Pharmaceuticals: Stock Price Drop Vs Disappointing Clinical Data Provides Good Upside
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), which plummeted 60% to $3.50 Thursday in reaction to a negative clinical readout, were rebounding Friday.
Spectrum Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) shares were halved on Thursday after the firm provided an update on its midstage cancer study.
Spectrum Pharmaceuticals Inc. shares fell 17% in premarket trade Thursday after the company said a mid-stage trial of a treatment for non-small cell lung cancer, or NSCLC, missed its main goal.
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?
As of late, it has definitely been a great time to be an investor in Spectrum Pharmaceuticals.
Investors need to pay close attention to Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.
Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joseph Turgeon on Q3 2019 Results - Earnings Call Transcript
Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.
Investors need to pay close attention to Spectrum Pharma (SPPI) stock based on the movements in the options market lately.
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?
Early ORR results in NSCLC with exon 20 mutation for lead candidate poziotinib pushed the stock over $20.00/share in 2018.
Early ORR results in NSCLC with exon 20 mutation for lead candidate poziotinib pushed the stock over $20.00/share in 2018.
Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.
Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q2 2019 Results - Earnings Call Transcript
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 28.13% and -349.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Spectrum Pharma (SPPI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers.
In the late 2000s, Spectrum captured the heightened demand of leucovorin shortage with Fusilev. This benefits patients while conferring shareholders one of the most prosperous periods in the c...
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
Spectrum Pharmaceuticals' (SPPI) CEO Joe Turgeon on Q1 2019 Results - Earnings Call Transcript
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?
Spectrum Pharmaceuticals had to withdraw its Biologics License Application (BLA) of ROLONTIS after the FDA requested additional information.
Spectrum Pharmaceuticals Inc. shares slid 7.6% in premarket trade Friday.
About SPPI
Spectrum Pharmaceuticals, a biopharma company, develops and commercializes oncology and hematology drug products. The company is developing ROLONTIS, a novel long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNá, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of relapsed or refractory non-Hodgkin's lymphoma patients, ... [Read more...]
| Industry Biotechnology | IPO Date Sep 26, 1996 |
| CEO Joseph W. Turgeon | Employees 146 |
| Stock Exchange NASDAQ | Ticker Symbol SPPI |
Analyst Forecasts
According to 6 analysts, the average rating for SPPI stock is "Buy." The 12-month stock price forecast is 10.40, which is an increase of 225.51% from the latest price.